The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • Events Calendar
    • Current Events
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • AIRR Community Meeting VIII – Decoding and Recoding Immunity
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Programs
    • Conferences
    • Competitions
      • Huston Award
        • Huston Award submission guidelines
      • Research Competition
      • Science Writing
    • Podcast
    • Webinars
  • Business Intelligence
    • Antibody Discovery & Development
      • Antibody Validation
      • Commercializing Antibody Therapeutics
      • Adaptive Immune Receptor Repertoires
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies to Watch
      • Antibodies in early-stage studies
    • Presentations
  • Learning and Career Center
    • Research Resources
      • Antibodies in late-stage clinical studies
    • Education Resources
    • Society Publications
    • Career Shorts
  • Members
    • Login
    • Note to members
    • Member discount codes
  • Sponsors & Partners
You are here: Home / Henk Jan van den Ham, Ph.D. & Lorenzo Fanchi, Ph.D.

Henk Jan van den Ham, Ph.D. & Lorenzo Fanchi, Ph.D.

Dr. Henk-Jan van den Ham leads ENPICOM’s Research Team. Henk-Jan studied Biomedical Sciences (Infection & Immunity) and moved from the wet into the dry lab to do a Ph.D. in Theoretical Immunology & Bioinformatics, both at Utrecht University, the Netherlands. He performed postdoctoral work at the department of Virology/Viroscience in Rotterdam, the Netherlands, where he used omics technologies and bioinformatics to study virus-host interactions.

At ENPICOM, Henk-Jan focuses on the latest developments in immunology and bioinformatics, specifically those within adaptive immune repertoire analysis and immunogenomics. This includes participation in academic and industry collaborative projects, grant applications, and contract research at the interface of immunology, bioinformatics, and software engineering. Henk-Jan also contributes guest lectures to various master programs, supervises master students, and participates in repertoire-related committees and several research networks.

 

As Team Lead Product Management at ENPICOM, Dr. Lorenzo Fanchi is responsible for the ongoing development of the IGX Platform, both by improving current apps and functionality, as well as by developing completely novel solutions to address new markets. He manages all phases of product development: from product discovery, envisioning and prototyping solutions to guiding development and implementation. Before products are launched to market, he is involved in guiding sales training and marketing/promotional activities.

Previously, during his Ph.D. at the Schumacher lab at the Netherlands Cancer Institute, Lorenzo worked on a variety of projects ranging from in vitro and in vivo work, where he explored approaches to improve adoptive cell therapy of cancer, to in silico projects which assessed the immunological foreignness of human cancers. Finally, he was involved in several clinical trials where he explored the use of repertoire sequencing data to identify therapy-induced changes in patients treated with immunotherapeutic intervention strategies.

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals